ArticleBioactive materials2026
Bioinspired 0D mitochondrial bioenergetic actuators rewire cartilage progenitor cell metabolism for osteoarthritis remission.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial dysfunction and consequent bioenergetic collapse in cartilage progenitor cells (CPCs), driven by excessive mitochondrial reactive oxygen species (ROS), constitute a fundamental barrier to endogenous cartilage regeneration and accelerate osteoarthritis (OA) progression. Accordingly, precise modulation of mitochondrial ROS is required to restore mitochondrial metabolic homeostasis. However, conventional antioxidant agents such as N-acetylcysteine (NAC) lack cell specificity and organelle-level precision, and exhibit limited bioavailability, thereby restricting their capacity to effectively reestablish mitochondrial metabolic homeostasis. Here, we engineer zero-dimensional (0D) bioinspired nanoassemblies, CPC membrane-coated (3-carboxypropyl)triphenylphosphonium bromide-functionalized NAC-derived carbon quantum dots (CM@TQDs), with capabilities for homotypic recognition and mitochondria-targeted metabolic reprogramming. Subsequently, CM@TQDs are encapsulated within ROS/pH-responsive hydrogel microspheres (HGCT), permitting inflammation-triggered release within the OA joint. Upon HGCT-mediated delivery and cellular internalization, the 0D nanoassemblies accumulate in mitochondria in a membrane potential-dependent manner, enhancing local mitochondrial bioavailability. Mechanistically, HGCT effectively scavenges mitochondrial ROS, restores oxidative phosphorylation, reestablishes tricarboxylic acid cycle flux, and suppresses aberrant glycolytic dependence. This metabolic restoration reactivates PI3K/AKT signaling, mitigates apoptosis and ferroptosis, and promotes CPC proliferation and chondrogenic differentiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.